Drugs & TargetsFree Foundation Medicine, Natera to advance personalized cancer monitoring September 27, 2019Vol.45 No.36
Drugs & TargetsFree Adaptive Biotechnologies, Amgen use clonoSEQ as preferred MRD test September 27, 2019Vol.45 No.36
Drugs & Targets FDA approves Keytruda + Lenvima for advanced endometrial carcinoma September 20, 2019Vol.45 No.35
Drugs & Targets FDA approves Erleada for metastatic castration-sensitive prostate cancer September 20, 2019Vol.45 No.35
Drugs & Targets NCTN trials clinically meaningful and cost-effective, study finds September 20, 2019Vol.45 No.35
Drugs & Targets Invitae offers no-charge genetic testing to patients with pancreatic cancer September 20, 2019Vol.45 No.35
Drugs & Targets Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma September 13, 2019Vol.45 No.34
Drugs & Targets BioXcel receives Orphan Drug Designation for BXCL701 in AML September 13, 2019Vol.45 No.34
Drugs & Targets Syapse, FDA form research collaboration on the regulatory use of real-world evidence September 06, 2019Vol.45 No.33
